BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

786 related articles for article (PubMed ID: 28628701)

  • 1. Trends in Receipt of Buprenorphine and Naltrexone for Opioid Use Disorder Among Adolescents and Young Adults, 2001-2014.
    Hadland SE; Wharam JF; Schuster MA; Zhang F; Samet JH; Larochelle MR
    JAMA Pediatr; 2017 Aug; 171(8):747-755. PubMed ID: 28628701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Receipt of Timely Addiction Treatment and Association of Early Medication Treatment With Retention in Care Among Youths With Opioid Use Disorder.
    Hadland SE; Bagley SM; Rodean J; Silverstein M; Levy S; Larochelle MR; Samet JH; Zima BT
    JAMA Pediatr; 2018 Nov; 172(11):1029-1037. PubMed ID: 30208470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of Racial and Ethnic Disparities in the Use of Medication to Treat Opioid Use Disorder Among Pregnant Women in Massachusetts.
    Schiff DM; Nielsen T; Hoeppner BB; Terplan M; Hansen H; Bernson D; Diop H; Bharel M; Krans EE; Selk S; Kelly JF; Wilens TE; Taveras EM
    JAMA Netw Open; 2020 May; 3(5):e205734. PubMed ID: 32453384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population.
    Morgan JR; Schackman BR; Leff JA; Linas BP; Walley AY
    J Subst Abuse Treat; 2018 Feb; 85():90-96. PubMed ID: 28733097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Racial and Ethnic Inequities in Buprenorphine and Methadone Utilization Among Reproductive-Age Women with Opioid Use Disorder: an Analysis of Multi-state Medicaid Claims in the USA.
    Xu KY; Schiff DM; Jones HE; Martin CE; Kelly JC; Bierut LJ; Carter EB; Grucza RA
    J Gen Intern Med; 2023 Dec; 38(16):3499-3508. PubMed ID: 37436568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of Medications for Treatment of Opioid Use Disorder Among US Medicaid Enrollees in 11 States, 2014-2018.
    ; Donohue JM; Jarlenski MP; Kim JY; Tang L; Ahrens K; Allen L; Austin A; Barnes AJ; Burns M; Chang CH; Clark S; Cole E; Crane D; Cunningham P; Idala D; Junker S; Lanier P; Mauk R; McDuffie MJ; Mohamoud S; Pauly N; Sheets L; Talbert J; Zivin K; Gordon AJ; Kennedy S
    JAMA; 2021 Jul; 326(2):154-164. PubMed ID: 34255008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pregnancy Rates Among Women Treated with Medication for Opioid Use Disorder.
    Bello JK; Xu KY; Salas J; Bedrick BS; Grucza RA
    J Gen Intern Med; 2024 Jun; 39(8):1342-1348. PubMed ID: 38424347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Opioid Use Disorder Treatment With Alcohol-Related Acute Events.
    Xu KY; Presnall N; Mintz CM; Borodovsky JT; Bhat NR; Bierut LJ; Grucza RA
    JAMA Netw Open; 2021 Feb; 4(2):e210061. PubMed ID: 33625511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative Effectiveness Associated With Buprenorphine and Naltrexone in Opioid Use Disorder and Cooccurring Polysubstance Use.
    Xu KY; Mintz CM; Presnall N; Bierut LJ; Grucza RA
    JAMA Netw Open; 2022 May; 5(5):e2211363. PubMed ID: 35536575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Receipt of medications for opioid use disorder among youth engaged in primary care: data from 6 health systems.
    Bagley SM; Chavez L; Braciszewski JM; Akolsile M; Boudreau DM; Lapham G; Campbell CI; Bart G; Yarborough BJH; Samet JH; Saxon AJ; Rossom RC; Binswanger IA; Murphy MT; Glass JE; Bradley KA;
    Addict Sci Clin Pract; 2021 Jul; 16(1):46. PubMed ID: 34233750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and treatment of opioid use disorders among primary care patients in six health systems.
    Lapham G; Boudreau DM; Johnson EA; Bobb JF; Matthews AG; McCormack J; Liu D; Samet JH; Saxon AJ; Campbell CI; Glass JE; Rossom RC; Murphy MT; Binswanger IA; Yarborough BJH; Bradley KA;
    Drug Alcohol Depend; 2020 Feb; 207():107732. PubMed ID: 31835068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trends in Urine Drug Monitoring Among Persons Receiving Long-Term Opioids and Persons with Opioid Use Disorder in the United States.
    Sohn M; Talbert JC; Huang Z; Oser C; Freeman PR
    Pain Physician; 2021 Mar; 24(2):E249-E256. PubMed ID: 33740362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder.
    Wakeman SE; Larochelle MR; Ameli O; Chaisson CE; McPheeters JT; Crown WH; Azocar F; Sanghavi DM
    JAMA Netw Open; 2020 Feb; 3(2):e1920622. PubMed ID: 32022884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Age related medication for addiction treatment (MAT) use for opioid use disorder among Medicaid-insured patients in New York.
    Neighbors CJ; Choi S; Healy S; Yerneni R; Sun T; Shapoval L
    Subst Abuse Treat Prev Policy; 2019 Jun; 14(1):28. PubMed ID: 31238952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are North Carolina clinicians delivering opioid use disorder treatment to Medicaid beneficiaries?
    Grove LR; Rao N; Domino ME
    Addiction; 2022 Nov; 117(11):2855-2863. PubMed ID: 35194878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
    Jones CM; Shoff C; Hodges K; Blanco C; Losby JL; Ling SM; Compton WM
    JAMA Psychiatry; 2022 Oct; 79(10):981-992. PubMed ID: 36044198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Receipt of Addiction Treatment After Opioid Overdose Among Medicaid-Enrolled Adolescents and Young Adults.
    Alinsky RH; Zima BT; Rodean J; Matson PA; Larochelle MR; Adger H; Bagley SM; Hadland SE
    JAMA Pediatr; 2020 Mar; 174(3):e195183. PubMed ID: 31905233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Buprenorphine prescribing for opioid use disorder in medical practices: can office-based out-patient care address the opiate crisis in the United States?
    Rhee TG; Rosenheck RA
    Addiction; 2019 Nov; 114(11):1992-1999. PubMed ID: 31307111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Racial Inequality in Receipt of Medications for Opioid Use Disorder.
    Barnett ML; Meara E; Lewinson T; Hardy B; Chyn D; Onsando M; Huskamp HA; Mehrotra A; Morden NE
    N Engl J Med; 2023 May; 388(19):1779-1789. PubMed ID: 37163624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiac and mortality outcome differences between methadone, buprenorphine and naltrexone prescriptions in patients with an opioid use disorder.
    Wang L; Volkow ND; Berger NA; Davis PB; Kaelber DC; Xu R
    J Clin Psychol; 2023 Dec; 79(12):2869-2883. PubMed ID: 37584532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.